This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome

Sponsored by National Taiwan University Hospital

About this trial

Last updated 11 years ago

Study ID

URIC

Status

Unknown status

Type

Observational

Placebo

No

Accepting

18-75 Years
20+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 12 years ago

What is this trial about?

Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease, but the exact mechanism remained to be elucidated. Many connective tissue diseases such as rheumatoid arthritis are often associated with antiphospholipid antibodies-associated endothelial impairment. In the present study, the investigators will analyze the presence of antiphospholipid antibodies in the serum of the patients with gout/asymptomatic hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia and gout. The investigators expect to find a correlation between these pathogenic antibody and those cardiovascular co-morbidities.

What are the participation requirements?

Yes

Inclusion Criteria

1. Patient with gouty arthritis

2. Patient with asymptomatic hyperurecemia

3. Patient of osteoarthritis but without hyperuricemia and gout